POD 4.1
Primary retroperitoneal lymph node dissection for metastatic non-seminomatous germ cell tumor: Review of oncological outcomes and the role of adjuvant chemotherapy
Ahmad Moosavi1, Lynn Anson-Cartwright1, Esthetu Atenafu1, Michael A.S. Jewett1, Philippe Bedard1, Maria Di Mania Jiang1, Rachel Glicksman1, Peter Chung1, Padraig Ward1, Martin O’Malley1, Susan Prendeville1, Robert J. Hamilton1
1Department of Surgical Oncology, Princess Margaret Cancer Centre Toronto Canada; 2Department of Genitourinary Oncology, Princess Margaret Cancer Centre, Toronto, Canada; 2Department of Medical Oncology, University of Toronto, Toronto, Canada; 2Department of Radiation Oncology, University of Toronto, Toronto, Canada

Introduction: There is renewed controversy regarding the role of adjuvant chemotherapy (AC) post-primary retroperitoneal lymph node dissection (pRPLND) in the management of pathologic stage (PS) II (pN1-3) non-seminomatous germ cell tumors (NSGCT). We compared the outcomes and treatment burden of pRPLND alone vs. pRPLND + AC in this setting.

Methods: A retrospective review of the Princess Margaret Cancer Centre cancer database identified men with PS II NSGCT after pRPLND between 1995-2020. The primary outcome was relapse-free survival (RFS). Secondary outcomes included disease-specific survival (DSS) and burden of relapse treatment. Uni- and multivariable analyses were conducted to identify factors associated with relapse.

Results: A total of 109 PS II patients were included in the study. There were 96 patients treated with pRPLND alone and 13 treated with pRPLND + AC. Median followup was 58 months. Of the 109 patients, 20 (18%) had pN1 and 89 (82%) had pN2/3 disease. The five-year RFS was 72% for the pRPLND-only group vs. 92% for the pRPLND + AC group (p=0.01). Within the pRPLND only group, five-year RFS differed by pN stage (pN1=94% vs. pN2/3=67%, p=0.03). The presence of extra-nodal extension in the RPLND specimen was associated with relapse (HR 3.97, 95% CI 1.68-9.36, p=0.002). Despite a higher relapse rate within the pRPLND-only group, DSS was similar at five years (98% pRPLND-only vs. 100% pRPLND + AC, p=0.48). Only 24 (25%) patients in the pRPLND-only group required any chemotherapy. Extrapolating our outcomes to compare a hypothetical group of 100 patients treated with pRPLND alone to 100 with pRPLND + AC, the overall burden of chemotherapy was substantially higher in the pRPLND + AC arm (246 vs. 79 cycles).

Conclusions: The majority of men with PS II NSGCT treated with pRPLND alone do not experience a recurrence or require systemic therapy. Despite a trend towards lower relapse risk when adjuvant chemotherapy is given, no difference in survival was seen but higher chemotherapy burden was entertained. Thus, AC for patients with PS II NSGCT may constitute over-treatment.

Acknowledgements: Financial support was provided by the Dell’Ece Family Testis Cancer Research Fund.

POD 4.2
Preoperative factors that predict upstaging in non-muscle-invasive bladder cancer patients undergoing radical cystectomy: Results from a multi-institutional Canadian cohort
Landon MacDonald1, Wassim Kassouf2, Rodney H. Breaux3, Adrian Fairey4, Agnhotram V. Ramanakumar5, Camilla Tajpler5, Darrel E. Drachenberg6, Jonathan Izawa7, Bobby Shyagay8, Jean-Baptiste Lattouf9, Michele Lodde10, D. Robert Siemens11, Claudia Jelkes12, Girish S. Kulkami13, Peter Chung1, Nimira Almahmoud14, Eric Hyndman15, Peter C. Black16, Rachel A. Robertson1
1Department of Urology, Dalhousie University, Halifax, Canada; 2Division of Urology, McGill University Health Center, Montreal, Canada; 3Division of Urology, University of Ottawa, Ottawa, Canada; 4Division of Urology, Cross Cancer Centre, Edmonton, Canada; 5Division of Urology, McGill University, Montreal, Canada; 6Section of Urology, Manitoba Cancer Centre, Winnipeg, Canada; 7Division of Urology, Western University, London, Canada; 8Division of Urology, McMaster University, Hamilton, Canada; 9Centre de Recherche du Chum, Université de Montréal, Montreal, Canada; 10Division of Urology, Université Laval, Quebec City, Canada; 11Department of Urology, Queen’s University, Kingston, Canada; 12Division of Urology, Université de Sherbrooke, Quebec City, Canada; 13Division of Urology, University of Toronto, Toronto, Canada; 14Department of Oncology, University of Calgary, Calgary, Canada; 15Division of Urology, Alberta Health Services, Calgary, Canada; 16Department of Urologic Sciences,University of British Columbia, Vancouver, Canada

Introduction: Outcomes associated with managing non-muscle-invasive bladder cancer (NMIBC) can be heterogeneous. Pathologic upstaging in the radical cystectomy (RC) specimen is identified in 30–50% of patients with clinical NMIBC. Our objective was to determine the predictive factors for upstaging among patients with clinical stage Ta or T1 tumors treated with cystectomy.

Methods: Using the Canadian Bladder Cancer information system (CBCis), we selected 341 patients with clinical stage <cT2N0M0 who underwent RC. This prospective database includes 7152 patients collected since 2015 from 14 Canadian centers in six provinces. Detailed information regarding the clinical stage, timelines, and results of RC was provided. Using descriptive and multivariable logistic regression, we determined the factors associated with upstaging to muscle-invasive-bladder cancer. Candidate variables included previous treatments, time from diagnosis to RC, histopathological features of the transurethrally resected bladder tumor (TURBT), and other patient characteristics.

Results: Upstaging at the time of RC was observed in 139 patients (41%). Of those who were upstaged, 62 (46.5%), 54 (38.9%), and 23 (16.6%) were found to have pT2, pT3, and pT4, respectively. Those who were upstaged had significantly higher rates in the TURBT specimen of concomitant CIS, lymphovascular invasion (LVI), and T1 tumor. Variant histology was associated with an increased risk of upstaging. The number of tumors was not different between groups; however, the upstaged group had significantly larger tumors. Soft-tissue positive margin rates on final pathology were substantially higher for the upstaged group. Post-RC complications were similar between groups (major complication rate: no upstaging, 8.4% vs. upstaging, 7.9%, p=0.25) and reflected values seen in the literature.

Conclusions: Using a contemporary cohort, we found that 41% of patients who underwent RC with clinical stage <cT2N0M0 were upstaged on final pathology. Tumor factors that may predict upstaging include CIS, LVI, tumor size, cT1, and variant histology.

Acknowledgements: This project was supported by the Canadian Bladder Cancer information system Collaborative (CBCis) and Bladder Cancer Canada. CBCis has received unrestricted grants or in-kind support from Bladder Cancer Canada, Merck, Roche, Asta Zenevca, Pfizer/EMD Serono, Seagen, and Bristol-Myers Squibb. There is no direct role or influence of this funding on this work.

POD 4.3
Experience of the virtual Canadian Testicular Cancer Second Opinion Group
Jesus Cendejas-Gomez1, Melissa Huynh1, Nicholas Power1
1Division of Urology, London Health Sciences Centre, London, Canada

Objective: In urological cancer (RC) the first line of treatment is for upstaged neoplasm worldwide in male patients 15–35 years, with an estimated 1100 men diagnosed annually in Canada. Despite the good prognosis, the complexity of the cases increases in the metastatic stages, and the implementation of evidence into the practice is more difficult and could potentially impact the long-term oncological outcomes. Implementing scientific evidence into clinical practice requires an active translational
process; a considerable number of studies emphasize the often-inadequate translation of evidence-based guidelines into clinical practice. Second-opinion groups have shown their utility in improving the implementation of evidence-based treatments. Our main objective is to analyze the utility of a second-opinion group in changing decision-making in patients with TC in Canada.

**Methods:** This is a retrospective analysis of 132 cases from the virtual Canadian Testicular Cancer Second Opinion Group. The discussion of cases was carried out anonymously on the Google groups platform, in which physicians from nine different provinces and different centers throughout Canada participate, including oncologists, uro-oncologists, and radiotherapists. Collected data include patients' demographic, histological, and treatment data. From the medical standpoint, the number of answers, type of question, measured concordance between first and second opinions, and finally change in treatments after the discussion was collected. The information was analyzed retrospectively from June 17, 2014, to July 1, 2022.

**Results:** We included 132 cases of patients with testicular tumors and extravaginal primary germ cell tumors (GCT) in Canada. The most common histology was GCT in 94% (124/132). Among these, non-seminomas represented 72.7% (96/124). The most common clinical stage was metastatic in 94.7%. The mean of second opinions (SO) per case was 4.7, 81% of seekers got responses from at least three different centers, and 56.8% of questions received a response from at least two different specialties. The average waiting time for the total of SO was less than one day. The questions came from academic centers in 81% of the cases; the most common seeker physicians were the oncologists, with 86.4% of the questions. The most frequent questions were related to chemotherapy in 49%, the sequence of treatment in 31%, and related surgery in 28%. Comparing the first and second opinions, we found 24% of overtreatment and 26% of undertreatment, with a surprising 52% potentially changing decision-making. We did not find statistically significant predictors in the multivariable analysis with binary logistic regression assessing for changing decision-making.

**Conclusions:** A second opinion group could be a very valuable and inexpensive tool to improve the implementation of evidence into practice in patients with complex testicular cancers, with an important percentage of potential changes in treatment even in academic cancer centers.

**References:**

**POD 4.4 Global variation in early recurrence after transurethral resection of bladder tumor in the RESECT study**

Betty Houjiazi Wang, Alex Kocik, Tim Wolk1, Kevin Gallagher1,2, Nikita Bhatt2, Keiran Clement1, Elektra Zimmermann1, Sinan Khaddour1, Fortis Goba6, Thines Anbarasan1, AlexanderNg1,4, Alexander Light15, Aqua Asi6, Vinson Chant2, Arjun Nathani1, Sabrina Ross1, Wendy Geng2, David Cooper5, Loma Aucot1, TimOBrien1, Steven MacLennan1, Matthew Nielsen1, Paramanathan Maniappan1, Veeru Kasivisvanathan1,4,6, Meghanahukami1; RESECT study global collaborators (BURST)

1Division of Urology, Department of Surgery, University of Alberta, Edmonton, Canada; 2Western General Hospital, Edinburgh, United Kingdom; 3British Urology Researchers in Surgical Training (BURST) Collaborative, United Kingdom; 4Norfolk and Norwich University Hospital, Norwich, United Kingdom; 5NHS Greater Glasgow & Clyde, Glasgow, United Kingdom; 6University Hospitals Plymouth, Plymouth, United Kingdom; 7University of Aberdeen, Aberdeen, United Kingdom; 8Howard T.H. Chan School of Public Health, Boston, United States; 9Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; 10University College London, London, United Kingdom; 11Imperial College London, London, United Kingdom; 12University of Leeds, Leeds, United Kingdom; 13University of Cambridge, Cambridge, United Kingdom; 14Guy’s and St. Thomas’ NHS foundation trust, London, United Kingdom; 15University of North Carolina School of Medicine, Chapel Hill, United States; 16University College London Hospitals NHS Foundation Trust, London, United Kingdom; 17St. George’s University Hospital, London, United Kingdom

**Introduction:** Transurethral resection of bladder tumor (TURBT) surgery is the first and most important step in the management of non-muscle-invasive bladder cancer (NMIBC). Our goal was to determine if there is significant variation in early recurrence (first-check cystoscopy) after TURBT between sites taking part in the RESECT study (NCT05154084) after accounting for tumor characteristics.

**Methods:** RESECT is an international, multicenter, observational study. A mixed-effects logistic regression model with tumor size, tumor number, and grade (all significantly and independently associated with early recurrence) (Table 1), there was significant residual variation attributable to site (p<0.0001, intra-class correlation 0.1). Adjustment for sites improved the regression model from an area under the receiver operating characteristic curve of 0.66 to 0.74.

**Conclusions:** There is significant variation in the early recurrence rate of NMIBC after TURBT surgery between sites that could not be explained by currently understood tumor features. This may be related to site-specific surgical techniques or perioperative practice. Further investigation is warranted to understand the influence of these factors.

**Acknowledgements:** Funding was provided by Rosetrees Trust, The Urology Foundation, Action Bladder Cancer UK, BJU International, Karl Starz, Photocure, Medoc Pharma.

**Table 1. Mixed effects logistic regression for early recurrence after first TURBT for NMIBC**

<table>
<thead>
<tr>
<th>Tumor feature</th>
<th>OR</th>
<th>p</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diameter(cm)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;1</td>
<td>1.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1–3</td>
<td>1.63</td>
<td>&lt;0.001</td>
<td>1.29–2.08</td>
</tr>
<tr>
<td>3–7</td>
<td>2.55</td>
<td>&lt;0.001</td>
<td>1.94–3.33</td>
</tr>
<tr>
<td>&gt;7</td>
<td>2.42</td>
<td>0.003</td>
<td>1.34–4.38</td>
</tr>
<tr>
<td>Number</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>1.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2–3</td>
<td>1.49</td>
<td>&lt;0.001</td>
<td>1.24–1.81</td>
</tr>
<tr>
<td>&gt;3</td>
<td>1.92</td>
<td>&lt;0.001</td>
<td>1.56–2.36</td>
</tr>
<tr>
<td>Stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ta</td>
<td>1.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tis</td>
<td>2.00</td>
<td>0.015</td>
<td>1.15–3.50</td>
</tr>
<tr>
<td>T1</td>
<td>1.90</td>
<td>&lt;0.001</td>
<td>1.57–2.30</td>
</tr>
<tr>
<td>Grade</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>1.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>High</td>
<td>1.44</td>
<td>&lt;0.001</td>
<td>1.19–1.73</td>
</tr>
<tr>
<td>Constant</td>
<td>0.07</td>
<td>&lt;0.001</td>
<td>0.06–0.09</td>
</tr>
<tr>
<td>Random intercept – site</td>
<td>0.36</td>
<td>0.16</td>
<td>0.23–0.57</td>
</tr>
</tbody>
</table>
All patients diagnosed with UTUC from February 1, 2012, to December 31, 2018, who underwent nephroureterectomy or segmental ureterectomy were identified. Pathology reports were obtained from the Manitoba Cancer Registry and the National Cancer Database. Staging and grading was done according to the TNM and GOG classification, respectively.

Methods: Univariate analysis was performed using chi-square or Fisher’s exact test to determine if there was association between various factors and disease progression. Multivariate logistic regression analysis was performed to determine independent predictors of disease progression.

Results: Of 4160 patients, use of partial nephrectomy was higher at sites with robotic access: 1376 (37.3%) compared to sites without robotic access 941 (33.6%) (RR 1.07, 95% CI 1.01–1.13, p=0.02 and aRR 1.03, 95% CI 0.97–1.09, p=0.35). In the subgroup treated with surgery, the proportion of partial nephrectomy was significantly higher in robotic sites (77.3% for robotic sites vs. 65.9% for non-robotic sites: RR 1.17, 95% CI 1.12–1.23, p<0.0001 and aRR 1.12, 95% CI 1.08–1.17, p=0.0001). Among partial nephrectomy patients, those treated at robotic sites used a minimally invasive approach more than patients treated at non-robotic sites (61.4% vs. 50.9%, RR 1.21, 95% CI 1.12–1.30, p<0.001). There was no significant difference in the proportion of patients treated with active surveillance between robotic (405, 16.9%) and non-robotic (258, 14.7%) sites (RR 1.15, 95% CI 0.99–1.32, p=0.16).

Conclusions: Access to robotic renal surgery was associated with increased use of partial nephrectomy and minimally invasive partial nephrectomy in the management of cT1 renal masses. The proportion of patients initially managed with active surveillance was not associated with robotic access.

POD 4.6
Radiographic predictors of muscle-invasive upper tract urothelial cancer: A Canadian cohort

David Chung, 1, Ryan Ramjowani, 1, Robert Wightman, 1, Jasmin (Jay) Nayak, 1, Jeffrey Scharczuk, 1, Rahul Bansal, 1, Andokinejad Ahmed, 1
Section of Urology, University of Manitoba, Winnipeg, Canada; 1Department of Pathology, University of Manitoba, Winnipeg, Canada

Introduction: Upper tract urothelial cancer (UTUC) is a rare and aggressive malignancy accounting for only 5% of all urothelial cancers. The association between diagnostic imaging findings and pathological findings at radical surgery is not well-established. The ability to accurately predict disease stage would aid in better selecting patients that are suitable for radical nephroureterectomy or a minimally invasive approach. Our objective was to analyze the preoperative radiological features associated with high-grade disease, lymmphovascular invasion (LVI), and higher-stage disease (≥pT2) at final pathology.

Methods: All patients diagnosed with UTUC from February 1, 2012, to December 31, 2018, who underwent nephroureterectomy or segmental ureterectomy were identified. Pathology reports were obtained from the Manitoba provincial pathology database. Preoperative patients’ radiologic characteristics, and pathological findings were recorded. Descriptive analysis was performed. Univariate logistic regression model was used to assess relationship between radiological findings and pathological outcomes of interest.

Results: A total of 113 pathology reports of patients with UTUC were obtained. Average age at time of diagnosis was 69.2±11.1 years. Patients were generally male, making up 59.8% of the cohort. Almost half (49.1%) of the tumors were located in the renal pelvis and 50.9% in the ureter. For laterality, 58 (51.8%) were right and one (0.9%) was bilateral. On univariate analysis, grade of tumor (p=0.001) and presence of hydronephrosis (p=0.049) were associated with high-grade disease, lymmphovascular invasion (LVI), and higher-stage disease (≥pT2), although none of these factors reached statistical significance. For predictors of LVI, the presence of hydronephrosis and pelvic tumor location was associated with locally invasive disease. For predictors of grade, severity of hydronephrosis (p=0.016), presence of hydronephrosis (p=0.015), and pelvic tumor location (p=0.015) were each independently associated with locally invasive disease. For predictors of grade, severity of hydronephrosis (p=0.016), presence of hydronephrosis (p=0.015), and pelvic tumor location (p=0.015) were each independently associated with locally invasive disease. For predictors of grade, severity of hydronephrosis (p=0.016), presence of hydronephrosis (p=0.015), and pelvic tumor location (p=0.015) were each independently associated with locally invasive disease.